Rigor Reviewed

Rigor-Reviewed Manuscript

Effect of a Reduced PCV10 Dose Schedule on Pneumococcal Carriage in Vietnam.

Name: Αlpha¹ Rigor Record — Effect of a Reduced PCV10 Dose Schedule on Pneumococcal Carriage in Vietnam.
Item: Effect of a Reduced PCV10 Dose Schedule on Pneumococcal Carriage in Vietnam.
Rating: 96
Author: Αlpha¹

Yoshida LM, Toizumi M, Nguyen HAT, Quilty BJ, Lien LT, Hoang LH, Iwasaki C, Takegata M, Kitamura N, Nation ML, Hinds J, van Zandvoort K, Ortika BD, Dunne EM, Satzke C, Do HT, Mulholland K, Flasche S, Dang DA

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2.5★ (Weak), 0 critical, 5 high issues for “Effect of a Reduced PCV10 Dose Schedule on Pneumococcal Carriage in Vietnam.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2.5 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★
CitationsUnresolved reference−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

No reported statistical tests were found to recompute.

Problems surfaced6 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions2

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

Data authenticity concerns1

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Broken references and links1

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted cluster-randomized non-inferiority trial with clear scientific premise, adequate design, and transparent reporting. The main weakness is the vague data availability statement, which lacks a concrete access mechanism. Minor reporting gaps include missing statistical software identification, lack of explicit reporting guideline adherence, and retrospective trial registration.

Both reviewers agreed on study type (interventional) and on all dimension statuses; no divergence required reconciliation. The statistics component checked 0 tests (none recomputable from reported statistics), so statistical correctness is not verified beyond the reported methods. The citation check found 1 reference not found in registry, which is a potential fabrication signal.

4 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites prior trials in England, South Africa, India, and Vietnam showing 1p+1 schedules induce similar post-booster protection, and identifies the gap in evidence for indirect protection. The rationale linking reduced-dose schedules to cost savings and sustainability is logical. Limitations of prior work (lack of evidence on indirect protection) are explicitly addressed as the study's motivation.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with prior work cited and a logical rationale for the study.

Evidence

direct quote[Introduction, paragraph 2]

“Trials in England, South Africa, India and Vietnam with either immunogenicity or carriage outcomes have demonstrated that a 1p+1 schedule indeed induces a similar protection to a 2p+1 schedule following administration of the booster dose, however, they also confirmed suspected inferiority before the booster.”